Ethics Review Committee Faculty of Allied Health Sciences University of Ruhuna, Galle, Sri Lanka.

Application Form

Instructions for Applicants

Postgraduate / Undergraduate candidates

All candidates are expected to complete an Ethics Review Application Form prior to the commencement of the research or collecting any data after the enrolment as a Research Candidate.

Faculty Staff members / Others

The Application form must be completed in full consultation with any supervisors/co-investigators/ research students/ prior to the commencement of the research or collecting any data.

This application form consists of two sections with two subsections:

Section I: General information – Details of the candidate

Section II: The research project

Section II A – Ethical issues on the research proposal

Section II B – Risks and benefits

Candidate must complete all three sections and attach the necessary documents at relevance.

For office use only	
Application No:	Date Received:
ERC Submission for	Date Decision
1.	
2.	
3.	
Name of Reviewers	Date Forwarded
1.	
2.	
3.	

SECTION I: GENERAL INFORMATION

1.	Title	of	the	Research	n Pro	iect

Location of Research	
Date of Commencement of Research	
Expected Date of Completion of Research	

2. Information of the Investigator				
2.1. Principal Investigator / researcher (Should be the applicant of ethics approval)				
Title (Rev./Prof./Dr./Ms.) Name:				
Institution/Department:				
Designation (Prof. Senior Lecturer,				
Research officer, Student etc.)				
Mailing address				
DI .				
Phone				
E-mail				
2.2. Co-investigator/ Co-researchers				
Are co-investigators/ co-researcher's involved? Yes / No				
If yes,				
Co-investigator I				
Title (Rev./Prof./Dr./Ms.) Name:				
Institution/Department:				
Designation (Prof. Senior Lecturer, Research				
officer, Student etc.)				
Mailing address				
Phone				
E-mail				
Co-investigator II				
Title (Rev./Prof./Dr./Ms.) Name:				
Institution/Department:				
Designation (Prof. Senior Lecturer, Research				
officer, Student etc.)				
Mailing address				

Please attach additional columns with the details of the co-investigators if necessary.

_	TAT (C . 1	1	•
٠.	Nature	Of the	research	nrolect
J.	Tatuic	OI the	1 CSCai CII	project

Phone E-mail

3.1. Is the project f	or an academic degree?	Yes / No
3.2. Is for an acade	mic degree specify:	

3.3. Have you already registered for this degree? Yes / No

3.4. If yes

Type of degree	
Awarding university	
Date of registration	

3.5. Nature of the study

a.	Laboratory based study with Human samples	
b.	Laboratory based study with Animals	
c.	Clinical trial	
d.	Observational study	
e.	Literature review	
f.		
g.		
h.		

4	Are there su	inervisors	for this	project?	Yes / No
┱.	Aic there st	aper visors	ioi uns	project:	103/110

4.1. Details of supervisors:

Principal supervisor

Title (Rev./Prof./Dr./	Mr./Ms.)	Name:		
Institution/Department	nt:			
Highest educational of	qualificatio	n		
Mailing address				
Phone			E-mail	

Co-supervisor

Title (Rev./Prof./Dr./M	(r./Ms.)	Name:		
Institution/Department:	•			
Highest educational qua	alificatio	n		
Mailing address				
Phone			E-mail	

Please append additional pages with supervisor's names if necessary

- 5. Location(s) where the research will be conducted:
 - 5.1. Is this a multi-site study? Yes / No
 - 5.2. Specify all study sites

If the research is to be conducted at a site requiring administrative approval/consent (eg.: in a hospital/school), it is the responsibility of the researcher to obtain approval prior to starting the project. (Attach letters)

Type of site (hospital/clinic/school/community etc.)	Details

- 6. Other research ethics committee approval(s)
 - 6.1. Has any other ERC approved this project? Yes / No *If yes, please attach a copy of the approval letter.*

7. Funding of this project.

8.

Funding status		Source and Amount	
Funded	Agency:	Agency: Total budget: SLR	
Applied for funding	Agency:	Total budget: SLR	
Unfunded	If unfunded, plea	If unfunded, please explain why no funding is needed.	

ripplica for fallaling		igency.
Unfunded	If	f unfunded, please explain why no funding is needed.
For clinical trials only.		
8.1. What is the phase	of the clinic	eal trial that is being conducted?
Phase I		
Phase II		
Phase III		
Phase IV (post ma	keting)	
Other		
If other specify:		
8.2. Is it a multicentre	trial?	Yes / No
If yes, list the othe		
ii jes, nst the stile	. triar brob.	
Dlagga attach athic	a approval f	from the energy or country of the everges
		from the sponsoring country or country of the overseas
principal investiga		
8.3. Is the clinical trial	registered v	with a clinical trials registry? Yes / No / Pending
If yes, give details		
Name of register		
Registration numb	er	
If no, give reasons		
7,8		
Q A Has this study bas	n annroyad	by the SCOCT (Subcommittee on Clinical Trials) at th
		•
Ministry of Health		Yes / No / Pending
If yes, give details	of Approva	al number
If no give reasons		
If no, give reasons		
8.5. Data safety monito	ring board	(only if available)
8.6. Details of indemni	ty and insu	rance coverage for participations, investigators and ethic
committee.	-	

SECTION II A: ETHICAL ISSUES ON THE RESEARCH PROPOSAL

9. Please include the following information as given in your project proposal indicating the page number(s) relevant to each section.

9.1. Collaborative partnership

	Applicable	Section in
	Yes / No	Protocol &
		page
The collaborations you have established with institutions		
where the study is to be conducted		
The collaborations you have established with the community		
where the study is to be conducted		
The benefits to institutions, communities, and participants in		
your research		

0 0			T 7		
9.2.	× 0	C12	- \/	alı	110
7.4.	L)()	Ciai	v	aı	uc

	1.1	Section in Protocol & page
The beneficiaries of your research and the benefit to them		
The plan for dissemination of study findings		

9.3. Scientific Validity

	Applicable Yes / No	Section in Protocol & page
The scientific importance of your study in relation to improving health care and/or knowledge on the subject.		
The justification for a replication study, if your study is a replication study.		
How the sample size was calculated		

9.4. Confidentiality

	Applicable	Section in
	Yes / No	Protocol &
		page
How the data and samples will be obtained		
How long data and samples will be kept		
Justification for collection of personal identification data		
Who will have access to the personal data of the research		
participants		
How the confidentiality of participants will be ensured		
The procedure for data and sample storage		
The procedure for data and sample disposal		

9.5. Rights of the participants

	Applicable Yes / No	Section in Protocol & page
Procedure for subjects to withdraw from the research at any time		
Procedure for subjects to ask questions and register complaints		
The contact person for research subjects		
Provisions for participants to be informed of results		
Provision to make the study product available to the study participants after research		

9.6. Fair participant selection

	1.1	Section in Protocol & page
The justification for the selection of the study population		
The inclusion and exclusion criteria		

9.7. Responsibilities of the researcher

	Applicable Yes / No	Section in Protocol & page
The provision of medical services to research participants with special reference to research/trial related injuries		
The provisions for continuation of care after the research is completed		
Declaration of conflicts of interests and how the investigators plan to manage the conflicts		
The ethical/legal/social and financial issues relevant to the study		

9.8. Vulnerable population

	Applicable Yes / No	Section in Protocol & page
Justification for conducting the study in this population		

9.9. Research funded by foreign agencies/companies

	Applicable Yes / No	Section in Protocol &
	1 es / No	
		page
Justification for conducting the study in Sri Lanka		
Relevance of the study to Sri Lanka		
Post research benefits to Sri Lanka		
The steps taken to take into account cultural and social		
customs, practices, and taboos in Sri Lanka		
The sharing of rights to intellectual property		
The fate of data and biological samples including whether		Please attach
they will be transferred abroad and what will happen to them		
after the conclusion of the study		
The materials transfer agreement, if biological material is to		Please attach
be transferred abroad		

9.10. Community based research

	Applicable Yes / No	Section in Protocol & page
The impact and relevance of the research on the community		
in which it is to be carried out		
The steps taken to consult with the concerned community		
during the design of the research		
The procedure used to obtain community consent		
The contribution to capacity building of the community		
The procedure for making available results of research to the		
community		

9.1<u>1</u>. Clinical trials

	Applicable	Section in
	Yes / No	Protocol &
		page
Justification for withdrawing any therapy from participants		
to prepare them for the trial		
Justification for withholding standard therapy from trial		
participants (e.g. control group)		
Justification for providing care which is not the standard of		
care		
Procedure for dealing with adverse events		
Procedure for reporting adverse events		
Measures in place for management of trial related injuries		
Provisions for safety monitoring		
Provisions/criteria for termination of the trial		
Provisions for making the trial drug available to participants		
after the trial if found to be effective		

9.12. Information Sheet (IFS) / Informed Consent Form (ICF) Check list

List the sections in IFS/ICF where you have dealt with the following	Section IFS/ICF
Purpose of the study	
Voluntary participation	
Duration, procedures of the study and participant's responsibilities	
Potential benefits	
Risks, hazards and discomforts	
Reimbursements	
Confidentiality	
Termination of study participation	

9.1	13	2	Consent
7.).	COHSCIII

	Applicable Yes / No	Section in Protocol & page
		1
The procedure for initial contact of participants*		
The procedure for obtaining informed consent		
Verbal		
Written		
The information (written/oral) provided to participants		
The procedure for ensuring that subjects have understood the		
information provided.		
The procedure for obtaining proxy consent.		
The procedure for withdrawing consent.		
Incentives/rewards/compensation provided to participants.		
The procedure for re-consenting if the research protocol		
changes during the course of research.		
The procedure for consenting if vulnerable groups / children		
under 18 years of age are being recruited.		
The procedure for consenting if children aged 12 – 18 years		
of age are being recruited. (for children aged 12-18 years in		
addition to parental consent, children's assent must be		
sought)**		

^{*} Attach a copy of all posters, advertisements, flyers, letters, to be used for recruitment.

10. Data collection

10.1. What is the procedure to be carried out on these subjects (give details of all study instruments to be used, collection of samples/blood/application of tests/administration of drugs etc, in detail).

Page number/s	
Section/s	

^{**} Please attach an assent form for children aged 12-18 years

- 11. Experience of investigators with this type of research.
 - 11.1. Please provide a brief description of previous experience with this type of research by (i) the principal investigator, (ii) the research team and (iii) the people who will have direct contact with the participants. If there has not been previous experience, please describe how the principal investigator/research team will be trained/prepared.

SECTION II B: RISKS AND BENEFITS

	Yes	No	arch:
substance): Psychological/emotional risks (feeling uncomfortable, embarrassed, upset):			
Social risks (e.g., loss of status, privacy and/or reputation):			
Legal risks (e.g., apprehension or arrest, subpoena):			
12.2. If yes to any of the above, please describe.			
10.0 0			. •
12.3. State measures employed during the procedure/study to re	move or i	ninimize	these
12.3. State measures employed during the procedure/study to rerisks	emove or i	minimize	these
	move or i	ninimize	these
	emove or 1	minimize	these
	emove or 1	minimize	these
risks	emove or i	minimize	these
risks Possible benefits			
risks Possible benefits Describe any potential direct benefits to participants fron			
risks Possible benefits Describe any potential direct benefits to participants from project	n their inv	olvement	in the
Possible benefits • Describe any potential direct benefits to participants from project • Describe any potential direct benefits to the community (n their inv	olvement	in the
Possible benefits • Describe any potential direct benefits to participants from project	n their inv	olvement	in the

14. Compensation

14.1. Will participants receive compensation for participation?

	Yes	No
Financial		
In-kind		
Other		

14.2.	If Yes, please provide details and justification for the amount or the value of the compensation offered.
14.3.	If No, please explain why compensation is not possible or inappropriate.
14.4.	If participants choose to withdraw, how will compensation be affected?
Pleas	back/debriefing/referral/after care se describe what information/feedback/services will be provided to participants and/or munities after their participation in the project is complete (e.g., health education, real to clinic/hospital, etc.)
If yes	ou have any conflict of interests with regards to this project? Yes / No s, please state below.
	nmercially
	ancially Ilectually
	er (Explain)
suppo	any member of the research team have any affiliation with the provider(s) of funding/ort, or a financial interest in the outcome of the research? Yes / No s, please explain:
	re is a duality of interest identified above describe the interest and state whether it itutes a potential conflict of interest.

Declaration of applicant

- As the Principal Investigator on this project, my signature confirms that I will ensure that all procedures performed under the project will be conducted in accordance with all relevant national and international policies and regulations that govern research involving human participants.
- I understand that if there is any deviation from the project as originally approved I must submit an amendment to the ERC for approval prior to its implementation.
- I have submitted all significant previous decisions by this or any other ERC and/or regulatory authorities relevant for the proposed study.
- I declare that I am not seeking approval for a study that has already commenced or has already been completed.
- I understand that at least two months are required for ethics review and granting of ethics clearance.
- I will submit progress reports/reports of adverse events and side effects as requested by the ERC of the Faculty of Allied Health Sciences.

		Date:/	
Signature of Principal Investigator			
Full name of Principal Investigator:			
Consen We, the undersigned hereby confirm that titled:		d to be co investigato	
Name	Qualifications	Institutional Affiliations	Signature
Acknowle	edgment (Office us		
Name of Applicant: (Prof/Dr/Mr/Ms)			
Application No		Date received/	/
Version:	be considered by be assigned to two	the Ethics Review (principal reviewers	Committee at its . The ERC may

Secretary /ERC, FAHS